Iovieno N, Dalton ED, Fava M, Mischoulon D (May 2011). “Second-tier natural antidepressants: review and critique”. 《Journal of Affective Disorders》 130 (3): 343–57. doi:10.1016/j.jad.2010.06.010. PMID20579741.
van Praag HM, van den Burg W, Bos ER, Dols LC (1974). “5-hydroxytryptophan in combination with clomipramine in "therapy-resistant" depressions”. 《Psychopharmacologia》 38 (3): 267–9. doi:10.1007/BF00421379. PMID4547418.
Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V (1990). “Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome”. 《J Int Med Res.》 18 (3): 201–9. doi:10.1177/030006059001800304. PMID2193835.
Thal LJ, Sharpless NS, Wolfson L, Katzman R (1980). “Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations”. 《Ann Neurol》 7: 570–6. doi:10.1002/ana.410070611. PMID6969054.
Trouillas P, Brudon F, Adeleine P (Nov 1988). “Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing”. 《Arch Neurol》 45 (11): 1217–22. doi:10.1001/archneur.1988.00520350055016. PMID3190503.
Gijsman HJ, van Gerven JM, de Kam ML, Schoemaker RC, Pieters MS, Weemaes M, de Rijk R, van der Post J, Cohen AF (April 2002). “Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers”. 《Journal of Clinical Psychopharmacology》 22 (2): 183–9. doi:10.1097/00004714-200204000-00012. PMID11910264.
Thombre AG (September 2005). “Assessment of the feasibility of oral controlled release in an exploratory development setting”. 《Drug Discovery Today》 10 (17): 1159–66. doi:10.1016/S1359-6446(05)03551-8. PMID16182208.
Byerley WF, Judd LL, Reimherr FW, Grosser BI (Jun 1987). “5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects”. 《J Clin Psychopharmacol》 7 (3): 127–37. doi:10.1097/00004714-198706000-00002. PMID3298325.
Izumi T, Iwamoto N, Kitaichi Y, Kato A, Inoue T, Koyama T (February 2006). “Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats”. 《European Journal of Pharmacology》 532 (3): 258–64. doi:10.1016/j.ejphar.2005.12.075. PMID16488409.
Jacobs GE, Kamerling IM, de Kam ML, Derijk RH, van Pelt J, Zitman FG, van Gerven JM (January 2010). “Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron”. 《Journal of Psychopharmacology》 24 (1): 65–72. doi:10.1177/0269881108094299. PMID18719048.
Turner EH, Loftis JM, Blackwell AD (Mar 2006). “Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan”. 《Pharmacol Ther.》 109 (3): 325–38. doi:10.1016/j.pharmthera.2005.06.004. PMID16023217.
Rondanelli M, Opizzi A, Faliva M, Bucci M, Perna S (March 2012). “Relationship between the absorption of 5-hydroxytryptophan from an integrated diet, by means of Griffonia simplicifolia extract, and the effect on satiety in overweight females after oral spray administration”. 《Eat Weight Disord.》 17 (1): e22–8. doi:10.3275/8165. PMID22142813.
Magnussen I, Nielsen-Kudsk F (April 1980). “Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in steady state”. 《Acta Pharmacologica et Toxicologica》 46 (4): 257–62. doi:10.1111/j.1600-0773.1980.tb02451.x. PMID6966118.
Magnussen I, Engbaek F (July 1978). “The effects of aromatic amino acid decarboxylase inhibitors on plasma concentrations of 5-hydroxytryptophan in man”. 《Acta Pharmacologica et Toxicologica》 43 (1): 36–42. doi:10.1111/j.1600-0773.1978.tb02229.x. PMID309271.
Westenberg HG, Gerritsen TW, Meijer BA, van Praag HM (December 1982). “Kinetics of l-5-hydroxytryptophan in healthy subjects”. 《Psychiatry Research》 7 (3): 373–85. doi:10.1016/0165-1781(82)90074-9. PMID6187038.
Rahman MK, Nagatsu T, Sakurai T, Hori S, Abe M, Matsuda M (October 1982). “Effect of pyridoxal phosphate deficiency on aromatic L-amino acid decarboxylase activity with L-DOPA and L-5-hydroxytryptophan as substrates in rats”. 《Japanese Journal of Pharmacology》 32 (5): 803–11. doi:10.1254/jjp.32.803. PMID6983619.
Bouchard S, Bousquet C, Roberge AG (September 1981). “Characteristics of dihydroxyphenylalanine/5-hydroxytryptophan decarboxylase activity in brain and liver of cat”. 《Journal of Neurochemistry》 37 (3): 781–7. doi:10.1111/j.1471-4159.1982.tb12555.x. PMID6974228.
Nakatani Y, Sato-Suzuki I, Tsujino N, Nakasato A, Seki Y, Fumoto M, Arita H (May 2008). “Augmented brain 5-HT crosses the blood-brain barrier through the 5-HT transporter in rat”. 《The European Journal of Neuroscience》 27 (9): 2466–72. doi:10.1111/j.1460-9568.2008.06201.x. PMID18445233.
Bouchard S, Roberge AG (July 1979). “Biochemical properties and kinetic parameters of dihydroxyphenylalanine--5-hydroxytryptophan decarboxylase in brain, liver, and adrenals of cat”. 《Canadian Journal of Biochemistry》 57 (7): 1014–8. doi:10.1139/o79-126. PMID39668.
Magnussen I, Jensen TS, Rand JH, Van Woert MH (September 1981). “Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man”. 《Acta Pharmacologica et Toxicologica》 49 (3): 184–9. doi:10.1111/j.1600-0773.1981.tb00890.x. PMID6175178.
Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK (October 1980). “Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa”. 《The New England Journal of Medicine》 303 (14): 782–7. doi:10.1056/NEJM198010023031403. PMID6997735.
Thombre AG (2005). “Assessment of the feasibility of oral controlled release in an exploratory development setting”. 《Drug Discov Today》 10 (17): 1159–66. doi:10.1016/S1359-6446(05)03551-8. PMID16182208.
Rondanelli M, Opizzi A, Faliva M, Bucci M, Perna S (March 2012). “Relationship between the absorption of 5-hydroxytryptophan from an integrated diet, by means of Griffonia simplicifolia extract, and the effect on satiety in overweight females after oral spray administration”. 《Eating and Weight Disorders》 17 (1): e22–8. doi:10.3275/8165. PMID22142813.
Iovieno N, Dalton ED, Fava M, Mischoulon D (May 2011). “Second-tier natural antidepressants: review and critique”. 《Journal of Affective Disorders》 130 (3): 343–57. doi:10.1016/j.jad.2010.06.010. PMID20579741.
van Praag HM (1982). “Serotonin precursors in the treatment of depression”. 《Advances in Biochemical Psychopharmacology》 34: 259–86. PMID6753514.
van Praag HM, van den Burg W, Bos ER, Dols LC (1974). “5-hydroxytryptophan in combination with clomipramine in "therapy-resistant" depressions”. 《Psychopharmacologia》 38 (3): 267–9. doi:10.1007/BF00421379. PMID4547418.
Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V (1990). “Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome”. 《J Int Med Res.》 18 (3): 201–9. doi:10.1177/030006059001800304. PMID2193835.
Thal LJ, Sharpless NS, Wolfson L, Katzman R (1980). “Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations”. 《Ann Neurol》 7: 570–6. doi:10.1002/ana.410070611. PMID6969054.
Trouillas P, Brudon F, Adeleine P (Nov 1988). “Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing”. 《Arch Neurol》 45 (11): 1217–22. doi:10.1001/archneur.1988.00520350055016. PMID3190503.
Gijsman HJ, van Gerven JM, de Kam ML, Schoemaker RC, Pieters MS, Weemaes M, de Rijk R, van der Post J, Cohen AF (April 2002). “Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers”. 《Journal of Clinical Psychopharmacology》 22 (2): 183–9. doi:10.1097/00004714-200204000-00012. PMID11910264.
Thombre AG (September 2005). “Assessment of the feasibility of oral controlled release in an exploratory development setting”. 《Drug Discovery Today》 10 (17): 1159–66. doi:10.1016/S1359-6446(05)03551-8. PMID16182208.
Byerley WF, Judd LL, Reimherr FW, Grosser BI (Jun 1987). “5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects”. 《J Clin Psychopharmacol》 7 (3): 127–37. doi:10.1097/00004714-198706000-00002. PMID3298325.
Izumi T, Iwamoto N, Kitaichi Y, Kato A, Inoue T, Koyama T (February 2006). “Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats”. 《European Journal of Pharmacology》 532 (3): 258–64. doi:10.1016/j.ejphar.2005.12.075. PMID16488409.
Jacobs GE, Kamerling IM, de Kam ML, Derijk RH, van Pelt J, Zitman FG, van Gerven JM (January 2010). “Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron”. 《Journal of Psychopharmacology》 24 (1): 65–72. doi:10.1177/0269881108094299. PMID18719048.
Turner EH, Loftis JM, Blackwell AD (Mar 2006). “Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan”. 《Pharmacol Ther.》 109 (3): 325–38. doi:10.1016/j.pharmthera.2005.06.004. PMID16023217.
Rondanelli M, Opizzi A, Faliva M, Bucci M, Perna S (March 2012). “Relationship between the absorption of 5-hydroxytryptophan from an integrated diet, by means of Griffonia simplicifolia extract, and the effect on satiety in overweight females after oral spray administration”. 《Eat Weight Disord.》 17 (1): e22–8. doi:10.3275/8165. PMID22142813.
Magnussen I, Nielsen-Kudsk F (April 1980). “Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in steady state”. 《Acta Pharmacologica et Toxicologica》 46 (4): 257–62. doi:10.1111/j.1600-0773.1980.tb02451.x. PMID6966118.
Magnussen I, Engbaek F (July 1978). “The effects of aromatic amino acid decarboxylase inhibitors on plasma concentrations of 5-hydroxytryptophan in man”. 《Acta Pharmacologica et Toxicologica》 43 (1): 36–42. doi:10.1111/j.1600-0773.1978.tb02229.x. PMID309271.
Westenberg HG, Gerritsen TW, Meijer BA, van Praag HM (December 1982). “Kinetics of l-5-hydroxytryptophan in healthy subjects”. 《Psychiatry Research》 7 (3): 373–85. doi:10.1016/0165-1781(82)90074-9. PMID6187038.
Rahman MK, Nagatsu T, Sakurai T, Hori S, Abe M, Matsuda M (October 1982). “Effect of pyridoxal phosphate deficiency on aromatic L-amino acid decarboxylase activity with L-DOPA and L-5-hydroxytryptophan as substrates in rats”. 《Japanese Journal of Pharmacology》 32 (5): 803–11. doi:10.1254/jjp.32.803. PMID6983619.
Bouchard S, Bousquet C, Roberge AG (September 1981). “Characteristics of dihydroxyphenylalanine/5-hydroxytryptophan decarboxylase activity in brain and liver of cat”. 《Journal of Neurochemistry》 37 (3): 781–7. doi:10.1111/j.1471-4159.1982.tb12555.x. PMID6974228.
Nakatani Y, Sato-Suzuki I, Tsujino N, Nakasato A, Seki Y, Fumoto M, Arita H (May 2008). “Augmented brain 5-HT crosses the blood-brain barrier through the 5-HT transporter in rat”. 《The European Journal of Neuroscience》 27 (9): 2466–72. doi:10.1111/j.1460-9568.2008.06201.x. PMID18445233.
Bouchard S, Roberge AG (July 1979). “Biochemical properties and kinetic parameters of dihydroxyphenylalanine--5-hydroxytryptophan decarboxylase in brain, liver, and adrenals of cat”. 《Canadian Journal of Biochemistry》 57 (7): 1014–8. doi:10.1139/o79-126. PMID39668.
Amamoto T, Sarai K (September 1976). “On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in plasma 5-HT and 5-HIAA levels and urinary 5-HIAA excretion following oral loading of L-5HTP in patients with depression”. 《Hiroshima Journal of Medical Sciences》 25 (2–3): 135–40. PMID1088369.
Magnussen I, Jensen TS, Rand JH, Van Woert MH (September 1981). “Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man”. 《Acta Pharmacologica et Toxicologica》 49 (3): 184–9. doi:10.1111/j.1600-0773.1981.tb00890.x. PMID6175178.
Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK (October 1980). “Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa”. 《The New England Journal of Medicine》 303 (14): 782–7. doi:10.1056/NEJM198010023031403. PMID6997735.
Thombre AG (2005). “Assessment of the feasibility of oral controlled release in an exploratory development setting”. 《Drug Discov Today》 10 (17): 1159–66. doi:10.1016/S1359-6446(05)03551-8. PMID16182208.
Emanuele E, Bertona M, Minoretti P, Geroldi D (2010). “An open-label trial of L-5-hydroxytryptophan in subjects with romantic stress”. 《Neuro Endocrinology Letters》 31 (5): 663–6. PMID21178946.
Rondanelli M, Opizzi A, Faliva M, Bucci M, Perna S (March 2012). “Relationship between the absorption of 5-hydroxytryptophan from an integrated diet, by means of Griffonia simplicifolia extract, and the effect on satiety in overweight females after oral spray administration”. 《Eating and Weight Disorders》 17 (1): e22–8. doi:10.3275/8165. PMID22142813.
nlm.nih.gov
“5-HTP”. 《U.S. National Library of Medicine》. 2015년 6월 7일에 확인함.
“5-Hydroxytryptophan”. University of Maryland Medical Center. 2010년 1월 6일에 원본 문서에서 보존된 문서. 2010년 1월 21일에 확인함.
“5-Hydroxytryptophan (5-HTP)”. 《A.D.A.M., Inc.》. University of Maryland Medical Center. Animated Dissection of Anatomy for Medicine, Inc. (A.D.A.M., Inc.) provided health and benefits information and technology to healthcare organizations, employers, consumers, and educational institutions
